Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias

MLL is a histone methyltransferase that can be converted into an oncoprotein by acquisition of transcriptional effector domains following heterologous protein fusions with a variety of nuclear transcription factors, cofactors, or chromatin remodeling proteins in acute leukemias. Here we demonstrate...

Full description

Saved in:
Bibliographic Details
Published inCancer cell Vol. 4; no. 2; pp. 99 - 110
Main Authors So, Chi Wai, Lin, Min, Ayton, Paul M, Chen, Everett H, Cleary, Michael L
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.08.2003
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:MLL is a histone methyltransferase that can be converted into an oncoprotein by acquisition of transcriptional effector domains following heterologous protein fusions with a variety of nuclear transcription factors, cofactors, or chromatin remodeling proteins in acute leukemias. Here we demonstrate an alternative mechanism for activation of MLL following fusions with proteins (AF1p/Eps15 and GAS7) that normally reside in the cytoplasm. The coiled-coil oligomerization domains of these proteins are necessary and sufficient for leukemogenic transformation induced by the respective MLL fusion proteins. Furthermore, homodimerization of MLL by synthetic dimerization modules mimics bona fide MLL fusion proteins resulting in Hox gene activation and enhanced self-renewal of hematopoietic progenitors. Our studies support an oligomerization-dependent mechanism for oncogenic conversion of MLL, presumably in part by recruitment of accessory factors through the dimerized MLL moiety of the chimeric protein.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1535-6108
1878-3686
DOI:10.1016/S1535-6108(03)00188-0